Erythropoietin induces miRNA‐210 by JAK2/STAT5 signaling in PBMCs of End‐stage Renal Disease patients
Open Access
- 20 March 2020
- journal article
- research article
- Published by Wiley in The FEBS Journal
- Vol. 287 (23), 5167-5182
- https://doi.org/10.1111/febs.15302
Abstract
Anemia of Chronic Kidney Disease is associated with blunted response/resistance to Erythropoietin Stimulating Agents (ESA) in hemodialysis patients (HD). Several molecules have been successful associated to ESA‐responsiveness; however, none of them is now considered a valid therapeutic biomarker of Erythropoietin resistance in these patients. We performed evaluation of the level of specific plasma circulating miRNAs in blood samples of HD, in relation to ESA treatment, with a follow up of one year (T0‐T3). We found significant lower circulating levels of all miRNAs analyzed at baseline (T0) in HD patients vs. Healthy Control (HC). The plasmatic levels of miRNA210 resulted significantly and negatively associated to Erythropoietin Resistance Index (ERI), and the variance of ΔmiRNA210 (miRNA210T3 minus miRNA210T0) explained significant percentage of ΔERI (ERIT3 minus ERIT0) variance. The Receiver Operating Characteristic analysis at T0, showed that the plasmatic level of miRNA210 could distinguish HD patients with positive or negative trend in ERI at T3. In vitro, recombinant human EPO induced significant release of miRNA210 from cultured PBMCs, through the activation of JAK2/STAT5 signaling, but not by the activation of the MAPK p38α and ERK1/2. In accordance, HD patients with negative ΔERI, showed higher level of p‐JAK2, and nuclear translocation of p‐STAT5 vs. patients with positive ΔERI or HC. Our data highlighted that chronic HD significantly reduces the circulating level of the miRNAs evaluated; within the targets analyzed, the miRNA210 could be considered a prognostic indicator of ESA responsiveness and index for anemia management.Keywords
This publication has 57 references indexed in Scilit:
- Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old TaleFrontiers in Cell and Developmental Biology, 2019
- The impact of dialysis therapy on older patients with advanced chronic kidney disease: a nationwide population-based studyBMC Medicine, 2014
- Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression AnalysisAmerican Journal of Kidney Diseases, 2013
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR StudyNephrology Dialysis Transplantation, 2006
- HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Erythropoietin Resistance in the Treatment of the Anemia of Chronic Renal FailureSeminars in Dialysis, 2006
- Anemia in chronic kidney disease: causes, diagnosis, treatment.Cleveland Clinic Journal of Medicine, 2006
- Reviews: Should the Target Hemoglobin for Patients with Chronic Kidney Disease Treated with Erythropoietic Replacement Therapy be Changed?Seminars in Dialysis, 2005
- Practice recommendations for the use of L-Carnitine in dialysis-related carnitine disorder National Kidney Foundation Carnitine Consensus ConferenceAmerican Journal of Kidney Diseases, 2003
- Hyporesponsiveness to recombinant human erythropoietinNephrology Dialysis Transplantation, 2001